FibroBiologics announces advancement in its cartilage repair program

FibroBiologics (FBLG) announced an advancement in its cartilage repair program. FibroBiologics has confirmed, through both immunohistochemistry and transcriptomic analysis, that the CYWC628 spheroids used in its wound healing program can be directly differentiated into chondrocytes, the specialized cells responsible for cartilage formation. This confirmation means that FibroBiologics can use its current CYWC628 master cell bank to produce a working cell bank and manufacture CybroCell, the company’s investigational cell therapy for the treatment of degenerative disc disease (DDD). This development allows FibroBiologics to move forward with amending its IND clearance with the FDA for the planned Phase I clinical trial for DDD and represents a major milestone in platform scalability.